Copyright © 2014, Evaluate Ltd, All rights reserved.

EP Vantage 2013 Pharma & Biotech, and MedTech Reviews

Based on EvaluatePharma and EvaluateMedTech Market Intelligence

EPV Pharma & Biotech 2013 in ReviewEP Vantage EP Vantage Pharma and Biotech 2013 in Review

The latest report by EP Vantage identifies the key trends that defined the pharmaceutical and biotech industry in 2013.

The cautious optimism of 2012 turned into a fully fledged biotech boom in 2013, marked by surging company valuations in the US and the opening of the IPO floodgates. The pharma and biotech sector also saw an increase in M&A deal values, buoyant licensing activity and sustained venture capital investment last year.

Download Pharma and Biotech 2013 in Review


EPV MedTech 2013 in ReviewEP Vantage EP Vantage MedTech 2013 in Review

EP Vantage’s latest report, MedTech 2013 in Review, reveals that 2013 has been an unlucky year in medtech.

At the half-year mark, the medtech sector was on course for its worst year in a decade in terms of M&A activity, EP Vantage concluded last fall in its Half Year Review 2013 report. Unfortunately, the second half of the year showed little sign of improvement.

Download MedTech 2013 in Review